aberrations and in good shape sufficient to tolerate FCR therapy, should still be very good candidates with the latter, With all the profit remaining this therapy could be done in 6 months while ibrutinib should be taken indefinitely.That notwithstanding, equally subtypes of MBL can have ‘CLL-certain’ genomic aberrations which include cytogenet